HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Aleman, T. S. Articles by Jacobson, S. G. Search for Related Content PubMed PubMed Citation Articles by Aleman, T. S. Articles by Jacobson, S. G.

Macular Pigment and Lutein Supplementation in ABCA4-Associated Retinal Degenerations

¹From the Scheie Eye Institute, Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania; the ²Department of Ophthalmology, University of California, San Francisco, California; and the ³Department of Ophthalmology, University of Iowa Carver College of Medicine, Iowa City, Iowa.

PURPOSE. To determine macular pigment (MP) optical density (OD) in patients with ABCA4-associated retinal degenerations (ABCA4-RD) and the response of MP and vision to supplementation with lutein.

METHODS. Patients with Stargardt disease or cone–rod dystrophy and known or suspected disease-causing mutations in the ABCA4 gene were included. All patients had foveal fixation. MPOD profiles were measured with heterochromatic flicker photometry. Serum carotenoids, visual acuity, foveal sensitivity, and retinal thickness were quantified. Changes in MPOD and central vision were determined in a subset of patients receiving oral supplementation with lutein for 6 months.

RESULTS. MPOD in patients ranged from normal to markedly abnormal. As a group, patients with ABCA4-RD had reduced foveal MPOD, and there was a strong correlation with retinal thickness. Average foveal tissue concentration of MP, estimated by dividing MPOD by retinal thickness, was normal in patients, whereas serum concentration of lutein and zeaxanthin was significantly lower than normal. After oral lutein supplementation for 6 months, 91% of the patients showed significant increases in serum lutein, and 63% of the patients’ eyes showed a significant augmentation in MPOD. The retinal responders tended to be female and to have lower serum lutein and zeaxanthin, lower MPOD, and greater retinal thickness at baseline. Responding eyes had significantly lower baseline MP concentration than did nonresponding eyes. Central vision was unchanged after the period of supplementation.

CONCLUSIONS. MP is strongly affected by the stage of ABCA4 disease leading to abnormal foveal architecture. MP could be augmented by supplemental lutein in some patients. There was no change in central vision after 6 months of lutein supplementation. Long-term influences of this supplement on the natural history of these macular degenerations require further study.

This article has been cited by other articles:

				A. V. Cideciyan, M. Swider, T. S. Aleman, Y. Tsybovsky, S. B. Schwartz, E. A.M. Windsor, A. J. Roman, A. Sumaroka, J. D. Steinberg, S. G. Jacobson, et al. ABCA4 disease progression and a proposed strategy for gene therapy Hum. Mol. Genet., March 1, 2009; 18(5): 931 - 941. [Abstract] [Full Text] [PDF]